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Abstract Angiotensinogen, a plasma serpin, functions as a
donor of the decapeptide angiotensin I, which is cleaved from the
N-terminus by renin. To assess the contribution of the serpin
framework to peptide cleavage we produced a chimaeric molecule
of K1-antitrypsin carrying the angiotensinogen N-terminus and
determined the kinetic parameters for angiotensin I release. The
Km for plasma angiotensinogen was 18-fold lower than for the
chimaeric protein while the catalytic efficiency was four-fold
higher. We also show that Cys-18 participates in a disulphide
bond and propose that constraints on the N-terminus profoundly
affect the interaction with renin.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The renin-angiotensin system is a major regulator of salt
and water homeostasis and has a key role in the control of
blood pressure. Epidemiological studies strongly implicate the
angiotensinogen gene locus in the pathogenesis of essential
hypertension. In particular, a polymorphism in the angioten-
sinogen promoter region changes the rate of transcription and
has been associated with hypertension [1]. Two further poly-
morphisms a¡ecting residues 174 and 235 within the coding
region are linked to hypertension and may cause structural
perturbations of angiotensinogen.
Angiotensinogen is the precursor of the angiotensin pep-
tides and is a non-inhibitory member of the serpin (serine
protease inhibitor) superfamily of proteins [2]. The core struc-
ture of angiotensinogen almost certainly resembles other ser-
pins and can therefore be modelled on family members such
as ovalbumin. However, the N-terminus of angiotensinogen is
considerably extended and its structure completely unknown.
The only function of angiotensinogen identi¢ed so far is to act
as a donor of the angiotensin I peptide in the ¢rst step of the
reaction sequence leading to the generation of angiotensin II.
In this step, angiotensinogen is cleaved at the N-terminus by
renin, an aspartyl protease. Two C-terminal amino acids are
then removed from angiotensin I by angiotensin-converting
enzyme (ACE) to produce the active octapeptide hormone
angiotensin II. This mediates its e¡ect on vascular pressure
by binding to cellular receptors and initiating a biochemical
cascade which, amongst other e¡ects, results in an increase in
vascular tone.
Although it is possible that angiotensinogen could be acting
solely as a passive carrier and plasma reservoir of the angio-
tensin peptide, the complexity of the serpin structure raises the
question of whether the remainder of the angiotensinogen
molecule has some additional function. Evidence for the in-
volvement of the protein structure in the renin interaction is
provided by an increased Km value for the interaction of renin
with the N-terminal tetradecapeptide of angiotensinogen [3,4]
compared to the value determined for the reaction of renin
with the whole angiotensinogen molecule. This ¢nding sug-
gests that the body of the angiotensinogen molecule facilitates
the interaction with renin thereby lowering the Km. In this
report, the role of the serpin body in the interaction between
angiotensinogen and renin has been studied by expressing a
chimaeric renin substrate in which the major protein frame-
work of angiotensinogen has been replaced with that of the
archetypal serpin, K1-antitrypsin. The 17 N-terminal amino
acids of angiotensinogen were added to the N-terminus of
K1-antitrypsin to produce the chimaeric Ang-Antitrypsin
(AngAT) protein. The substitution of the angiotensinogen
protein framework by the K1-antitrypsin molecule signi¢cantly
alters the kinetics of the interaction with renin and release of
angiotensin I.
Fig. 1 shows a model of the angiotensinogen structure
based on the crystal structure of ovalbumin, another non-in-
hibitory serpin [5,6], with which angiotensinogen has 21%
sequence homology [7]. The extended N-terminus of angioten-
sinogen contains a cysteine residue at position 18, and in this
report we present evidence that this cysteine residue is disul-
phide linked to the body of the molecule, thereby constraining
the N-terminal extension containing the angiotensin peptide.
2. Materials and methods
2.1. Bacterial strains and growth conditions
E. coli (BL21(DE3)pLysS) were grown in 2UTY medium (1.6% w/v
bacto-tryptone, 1% w/v bacto-yeast extract, 0.5% w/v NaCl) supple-
mented with 50 Wg/ml ampicillin.
2.2. Construction of the pAngAT expression vector
The pAngAT expression vector was constructed from the K1-anti-
trypsin expression vector, pTermAT [8], by insertion of a cassette
encoding the sequence of the 17 N-terminal amino acids of angioten-
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sinogen. The cassette was prepared by annealing the two synthetic
oligonucleotides: 5P-GAT CGA GTA TAT ATA CAT CCC TTC
CAC CTC GTC ATC CAC AAT GAG AGT ACC-3P and 5P-CT
CAT ATA TAT GTA GGG AAG GTG GAG CAG TAG GTG
TTA CTC TCA TGG CTA G-3P, and ligating into a BamHI site
immediately preceding the K1-antitrypsin coding sequence. The con-
struct was con¢rmed by DNA sequencing.
2.3. Expression and puri¢cation of the AngAT protein
BL21(DE3)pLysS cells transformed with pAngAT were grown at
37‡C to an OD600 of 0.4 and induced by the addition of IPTG for the
expression of AngAT. Cells were harvested after 3 h, the pellet resus-
pended in 300 mM NaCl, 50 mM Tris pH 8.0, 10 mM EDTA, 0.5%
Triton X-100 and cells lysed by French press. The sample was centri-
fuged and the pellet washed three times in lysis bu¡er (30 ml). The
¢nal pellet was dissolved in 5 ml (8 M GdHCl, 100 mM DTT, 50 mM
Tris pH 8.0) and centrifuged. The soluble denatured protein was re-
folded by pumping into 800 ml 50 mM Tris pH 8.0, 5 mM DTT at a
rate of 0.01 ml/min. Insoluble material was removed by centrifugation
and the supernatant passed through a 0.2 Wm ¢lter. The refolded
protein was applied to a column (1.6U16.5 cm) of Q-Sepharose
fast-£ow (Pharmacia Biotech, Uppsala, Sweden) and eluted with a
gradient of 50^250 mM NaCl in 50 mM Tris pH 8.0. Fractions con-
taining AngAT were identi¢ed by rocket immunoelectrophoresis using
antibodies to antitrypsin, and the pooled puri¢ed AngAT was ana-
lysed by SDS-PAGE and Western blotting.
2.4. Characterisation of AngAT
Puri¢ed AngAT was characterised by determining its activity as a
functional antitrypsin molecule. Inhibition of bovine chymotrypsin
was measured as described in Lomas et al., 1993 [9]. N-terminal se-
quencing of the puri¢ed AngAT protein and renin-cleaved N-terminal
peptide were performed on an Applied Biosystems 477 Protein Se-
quencer. The cleaved peptide was additionally con¢rmed by mass
spectrometry using a Kratos Kompact MALDI 4 instrument.
2.5. Renin kinetics
The renin substrates were incubated with recombinant human renin
(5 nM for AngAT, 1 nM for plasma angiotensinogen [10] and 0.5 nM
for TDP (Calbiochem Novabiochem, UK)) for 15 min at 37‡C in
0.2 M sodium phosphate bu¡er pH 7.4, 0.02% BSA. The reaction
was stopped by the addition of 1/10 volume 10% H3PO4 and samples
kept on ice. Angiotensin I was quanti¢ed by reverse phase HPLC of a
known volume of reaction product on a Novapak C18 column
(Waters Division of Millipore, UK), eluting with an acetonitrile
gradient (19^50% in 1% H3PO4) over 10 min. A standard curve was
prepared using pure angiotensin I peptide (Calbiochem Novabiochem,
UK). A single site binding equation (GraphPad Software) was used to
construct Michaelis-Menten plots from the experimental data and
thus determine Km and Vmax values.
2.6. Determination of angiotensinogen disulphide bonds
Two 20 Wg samples of pure plasma angiotensinogen were placed in
Eppendorf tubes, dried in a vacuum centrifuge and each resuspended
in 50 Wl 6 M GdHCl, 0.25 M Tris pH 8.5. To one of the protein
samples, 2.5 Wl 10% v/v L-mercaptoethanol was added, the tube
£ushed with nitrogen, sealed and left at room temperature (RT) in
the dark for 2 h. After this time, 18.6 Wmol of the sulphydryl modify-
ing reagent 4-vinyl pyridine (4-VP) was added, the tube again £ushed
with nitrogen and incubated for a further 2 h in the dark at RT. The
second protein sample was treated directly with the 4-VP reagent as
described, without the initial reduction step. At the end of the reac-
tion, urea and excess reagents were removed from the samples by
repeated dilution with H2O and reconcentration in a centrifugal con-
centrator. The ¢nal concentrated protein samples were subjected to N-
terminal sequence analysis.
3. Results and discussion
Expression of the chimaeric Ang-Antitrypsin (AngAT) in
bacteria resulted in the majority of the expressed protein being
in the form of insoluble cytoplasmic inclusion bodies which
has been observed previously with recombinant antitrypsin
[11]. In order to enable functional studies, the insoluble Ang-
AT protein was refolded and puri¢ed on Q-Sepharose resin
(Fig. 2). N-terminal sequence analysis con¢rmed the sequence
M-D-R-V-Y-I-H-P-F-H-L-V-I-H-N-E-S-T-D-P, correspond-
ing to the 17 N-terminal amino acids of angiotensinogen
with the retention of the initiating methionine residue as a
result of prokaryotic expression. The angiotensinogen N-ter-
minus is followed by the N-terminal amino acid sequence of
antitrypsin, beginning with aspartate and proline. AngAT was
shown to be active as an inhibitor of bovine K-chymotrypsin
with a speci¢c activity of 46.8% and a Kass of 2.5U106 M31
s31. These ¢gures are comparable with those obtained for
puri¢ed plasma antitrypsin, indicating that the serpin body
of K1-antitrypsin is correctly refolded. Upon cleavage of Ang-
AT with renin, a peptide of mass 1428.1 þ 1 Da was released,
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Fig. 1. Model of angiotensinogen structure based on sequence align-
ment with ovalbumin. The 69 N-terminal amino acids are not in-
cluded in the model but the diagram illustrates the constraint which
may be imposed by a disulphide bond between Cys-18 and Cys-138.
Fig. 2. SDS-PAGE analysis of puri¢ed AngAT. Lane 1: Coomassie
stained; Lane 2: Western blotted with antibody to antitrypsin. Lane
2 contains 1/10 quantity of protein in lane 1.
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corresponding to the decapeptide angiotensin I, with an addi-
tional N-terminal methionine residue and this was con¢rmed
by N-terminal sequence analysis.
In order to determine the values of Km and Vmax for the
AngAT-renin reaction, increasing concentrations of AngAT
were incubated with 5 nM recombinant human renin and a
known volume of each reaction mixture was analysed by re-
verse phase HPLC. The quantity of Met-angiotensin I re-
leased was calculated and from the resulting Michaelis-Ment-
en plot (Fig. 3), Km and Vmax values for the reaction of
AngAT with recombinant human renin were calculated to
be 47.5 þ 4.2 WM and 566.2 þ 34.0 nmol/l/min respectively.
The signi¢cance of these values of Km and Vmax can be
assessed by comparison with the kinetic parameters for the
reaction of recombinant human renin with other substrates.
The Km for AngAT is considerably higher than the values
determined for plasma angiotensinogen (Km = 2.6 þ 0.6 WM)
(Fig. 3). Comparison of Km values indicate that renin has a
higher a⁄nity for angiotensinogen than for AngAT. This im-
plies that the body of the angiotensinogen molecule contrib-
utes to the interaction with renin and is not simply a passive
carrier of the N-terminal peptide. Renin also cleaves a syn-
thetic angiotensinogen N-terminal tetradecapeptide (TDP)
substrate, with a Km of 8.2 WM (Fig. 3). The fact that the
Km for renin interaction with AngAT is higher than that for
the interaction of renin with TDP indicates that the K1-anti-
trypsin serpin body of AngAT actually has a negative e¡ect
on the association with renin. In order to compare the Vmax
values obtained for plasma angiotensinogen, AngAT and
TDP we need to take into consideration the concentration
of enzyme used in the assays. Although we have not measured
the speci¢c activity of our renin, if we assume it to be fully
active then Kcat values for the substrate would be 0.4 s31
(plasma angiotensinogen), 1.9 s31 (AngAT) and 2.3 s31
(TDP) and catalytic e⁄ciencies (Kcat/Km) are 0.2 WM31 s31,
0.04 WM31 s31 and 0.3 WM31 s31 respectively. These ¢gures
show that the Kcat for AngAT is approximately ¢ve-fold high-
er than for plasma angiotensinogen, indicating that the renin-
substrate complex dissociates to form products faster for An-
gAT than angiotensinogen. By contrast, when catalytic e⁄-
ciency is calculated, plasma angiotensinogen is approximately
four-fold greater. This di¡erence is most notable at the phys-
iological concentration of plasma angiotensinogen where it is
a much better substrate for renin than AngAT.
The behaviour of these serpins as substrates may be ex-
plained by speci¢c interactions occurring between renin and
angiotensinogen at sites away from the scissile bond or by
structural constraints imposed upon the N-terminal region
by the body of the molecule. The lack of a crystal structure
for angiotensinogen makes it di⁄cult to speculate about the
conformation adopted by the N-terminus and the nature of its
interaction with the serpin body. However, we noted the pres-
ence of a cysteine residue at position 18 with the potential to
participate in a stabilising intramolecular disulphide bond. To
investigate this possibility we assessed the availability of Cys-
18 for reaction with the sulphydryl modifying reagent, 4-vinyl
pyridine (4-VP) under reducing and non-reducing conditions.
N-terminal sequence analysis of plasma angiotensinogen
reacted with 4-VP under reducing conditions detected a pyr-
idylethylcysteine residue while under non-reducing conditions
Cys-18 was not detected at all, due to its involvement in a
disulphide bond. Taking these data together with the mod-
elled angiotensinogen structure (Fig. 1), we propose that the
angiotensinogen N-terminus is linked to the rest of the mole-
cule by a disulphide link between Cys-18 and Cys-138. In
support of this proposal, these two residues are conserved in
rat, mouse, sheep and human angiotensinogens. The con-
straint imposed by this disulphide bond may contribute to
the N-terminus adopting a favourable conformation for for-
mation of a Michaelis-Menten complex with renin. Since only
the 17 N-terminal amino acids of angiotensinogen were at-
tached to K1-antitrypsin, AngAT does not have the potential
to form such an interaction. It is also possible that the lack of
N-terminal constraint explains the faster release of angioten-
sin I from AngAT.
Angiotensinogen interacts with renin to release the decap-
eptide angiotensin I at a Km close to the plasma concentration
of angiotensinogen [12]. Since the cleavage of angiotensinogen
by renin is rate-limiting in the renin-angiotensin system [13]
the kinetics of this interaction are of obvious importance and
in this report the tertiary structure of angiotensinogen has
been shown to profoundly a¡ect the a⁄nity of enzyme for
substrate as well as the overall rate of reaction. Furthermore,
the demonstration that another serpin molecule can act as a
donor of angiotensin I has many more general implications
for the design of peptide therapies.
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